Ilekudinol C

Ilekudinol C

SCHEMBL3506041

C=C(C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CCC(O)C(C)(CO)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 4/20 0.85
▸ TOP2A P11388 2/20 0.85
▸ USP2 O75604 2/20 0.85
▸ LMNA P02545 2/20 0.85
▸ HIF1A Q16665 2/20 0.85
▸ NT5E P21589 2/20 0.85
▸ RELA Q04206 1/20 0.85
▸ CES2 O00748 2/20 0.75
▸ CES1 P23141 2/20 0.75
▸ F3 P13726 2/20 0.75
▸ PTGES O14684 2/20 0.65
▸ ALB P02768 2/20 0.59
▸ AKR1B10 O60218 1/20 0.59
▸ POLB P06746 1/20 0.59
▸ GLI1 P08151 1/20 0.59
▸ AKR1B1 P15121 1/20 0.59
▸ DPP4 P27487 1/20 0.59
▸ RORC P51449 1/20 0.59
▸ GPBAR1 Q8TDU6 1/20 0.59
▸ SAE1 Q9UBE0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ilekudinol C SCHEMBL15450693 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
Ilekudinol C SCHEMBL16704973 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
Ilekudinol C SCHEMBL13293203 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
Ilekudinol C SCHEMBL13164841 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
Ilekudinol C SCHEMBL14023084 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
Ilekudinol C SCHEMBL15457041 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
Ilekudinol C SCHEMBL3131495 1.00 PTPN1 (0.85) PTPN1TOP2AUSP2LMNAHIF1A
SCHEMBL16704646 0.95 PTPN1 (0.76) PTPN1TOP2AUSP2LMNAHIF1A
SCHEMBL15456878 0.95 PTPN1 (0.76) PTPN1TOP2AUSP2LMNAHIF1A
SCHEMBL15445083 0.95 PTPN1 (0.76) PTPN1TOP2AUSP2LMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642567-B2 Receptor modulators exhibiting neuroprotective and memory enhancing activities THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2014-02-04 — — US disclosed
US-8637474-B2 Receptor modulators exhibiting neuroprotective and memory enhancing activities THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) 2014-01-28 — — US disclosed
US-20130012462-A1 RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) 2013-01-10 — — US disclosed
US-20100222286-A1 RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES THE HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) 2010-09-02 — — US disclosed
WO-2008138200-A1 NMDA AND MC RECEPTOR ANTAGONISTS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012462-A1 RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES GRIN1, GRIN2A, GRM1 PTPN1 3740/4885TOP2A 4247/4885USP2 3517/4885
US-20100222286-A1 RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES GRIN1, GRIN2A, GRM1 PTPN1 3740/4885TOP2A 4247/4885USP2 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback